Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Inclusion Criteria:

1. Signed written informed consent.

2. Histologically or cytologically proven metastatic, recurrent or locally advanced selected solid tumors.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months.

4. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST v1.1.

5. Adequate organ functions.

6. Must have progressed after prior line of treatment.

Exclusion Criteria (all participants):

1. Participants with known symptomatic brain metastases.

2. Participant had systemic therapy or radiation therapy within 2 weeks prior to the first dose of study drug.

3. Women who are pregnant or lactating.